Matches in SemOpenAlex for { <https://semopenalex.org/work/W3162289786> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W3162289786 endingPage "331" @default.
- W3162289786 startingPage "326" @default.
- W3162289786 abstract "Objective: To analyze the clinical efficacy and safety of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma (HCC). Methods: Ninety-four cases with mid-and advanced-stage HCC who received camrelizumab combined with apatinib as second-line treatment were enrolled. Routine blood test, blood biochemical indexes, tumor stage, tumor imaging characteristics, previous treatment strategies and other clinical data before treatment were documented. Imaging examination follow-up results and adverse reactions during treatment were followed up until the end of follow-up or loss of follow-up or death. Kaplan-Meier method was used to analyze the clinical efficacy. Results: As of the last follow-up, 94 cases with mid-and advanced-stage HCC had received camrelizumab combined with apatinib as second-line treatment. Among them, 15 cases were lost to follow-up, 31 cases died, and 48 cases survived. The overall remission rate was 31.9%. The overall disease control rate was 71.3%. The median time to disease-free progression was 6.6 months. The median time to disease progression was not yet available. The 1-year cumulative survival rate was 62.3%. Grade 3 and above adverse reactions mainly included were thrombocytopenia (7.4%), abdominal pain (4.3%), active hepatitis (4.3%), leukopenia (4.3%), diarrhea (3.2%), hand-foot syndrome (3.2%). All adverse reactions were effectively controlled. Conclusion: Camrelizumab combined with apatinib can effectively prolong the survival period of patients with mid-and advanced-stage HCC, and it is well tolerated." @default.
- W3162289786 created "2021-05-24" @default.
- W3162289786 creator A5007767899 @default.
- W3162289786 creator A5008889064 @default.
- W3162289786 creator A5030223228 @default.
- W3162289786 creator A5034017949 @default.
- W3162289786 creator A5050750924 @default.
- W3162289786 creator A5052930637 @default.
- W3162289786 creator A5054162710 @default.
- W3162289786 creator A5061224644 @default.
- W3162289786 creator A5065183161 @default.
- W3162289786 creator A5071316194 @default.
- W3162289786 creator A5078000842 @default.
- W3162289786 date "2021-04-20" @default.
- W3162289786 modified "2023-10-17" @default.
- W3162289786 title "[Clinical efficacy and safety analysis of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma: a multicenter retrospective study]." @default.
- W3162289786 doi "https://doi.org/10.3760/cma.j.cn501113-20210329-00148" @default.
- W3162289786 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33979958" @default.
- W3162289786 hasPublicationYear "2021" @default.
- W3162289786 type Work @default.
- W3162289786 sameAs 3162289786 @default.
- W3162289786 citedByCount "4" @default.
- W3162289786 countsByYear W31622897862022 @default.
- W3162289786 countsByYear W31622897862023 @default.
- W3162289786 crossrefType "journal-article" @default.
- W3162289786 hasAuthorship W3162289786A5007767899 @default.
- W3162289786 hasAuthorship W3162289786A5008889064 @default.
- W3162289786 hasAuthorship W3162289786A5030223228 @default.
- W3162289786 hasAuthorship W3162289786A5034017949 @default.
- W3162289786 hasAuthorship W3162289786A5050750924 @default.
- W3162289786 hasAuthorship W3162289786A5052930637 @default.
- W3162289786 hasAuthorship W3162289786A5054162710 @default.
- W3162289786 hasAuthorship W3162289786A5061224644 @default.
- W3162289786 hasAuthorship W3162289786A5065183161 @default.
- W3162289786 hasAuthorship W3162289786A5071316194 @default.
- W3162289786 hasAuthorship W3162289786A5078000842 @default.
- W3162289786 hasConcept C126322002 @default.
- W3162289786 hasConcept C141071460 @default.
- W3162289786 hasConcept C143998085 @default.
- W3162289786 hasConcept C146357865 @default.
- W3162289786 hasConcept C151730666 @default.
- W3162289786 hasConcept C197934379 @default.
- W3162289786 hasConcept C2776283816 @default.
- W3162289786 hasConcept C2776694085 @default.
- W3162289786 hasConcept C2778019345 @default.
- W3162289786 hasConcept C2780668389 @default.
- W3162289786 hasConcept C2780739268 @default.
- W3162289786 hasConcept C2780873365 @default.
- W3162289786 hasConcept C71924100 @default.
- W3162289786 hasConcept C86803240 @default.
- W3162289786 hasConcept C90924648 @default.
- W3162289786 hasConceptScore W3162289786C126322002 @default.
- W3162289786 hasConceptScore W3162289786C141071460 @default.
- W3162289786 hasConceptScore W3162289786C143998085 @default.
- W3162289786 hasConceptScore W3162289786C146357865 @default.
- W3162289786 hasConceptScore W3162289786C151730666 @default.
- W3162289786 hasConceptScore W3162289786C197934379 @default.
- W3162289786 hasConceptScore W3162289786C2776283816 @default.
- W3162289786 hasConceptScore W3162289786C2776694085 @default.
- W3162289786 hasConceptScore W3162289786C2778019345 @default.
- W3162289786 hasConceptScore W3162289786C2780668389 @default.
- W3162289786 hasConceptScore W3162289786C2780739268 @default.
- W3162289786 hasConceptScore W3162289786C2780873365 @default.
- W3162289786 hasConceptScore W3162289786C71924100 @default.
- W3162289786 hasConceptScore W3162289786C86803240 @default.
- W3162289786 hasConceptScore W3162289786C90924648 @default.
- W3162289786 hasIssue "4" @default.
- W3162289786 hasLocation W31622897861 @default.
- W3162289786 hasOpenAccess W3162289786 @default.
- W3162289786 hasPrimaryLocation W31622897861 @default.
- W3162289786 hasVolume "29" @default.
- W3162289786 isParatext "false" @default.
- W3162289786 isRetracted "false" @default.
- W3162289786 magId "3162289786" @default.
- W3162289786 workType "article" @default.